Zobrazeno 1 - 10 of 23 pro vyhledávání: '"Ignasi Pau-Charles"'
1
Akademický článek
Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials
Autor: Jennifer Soung, Sonja Ständer, Jan Gutermuth, Ignasi Pau-Charles, Zach Dawson, Fan Emily Yang, Luna Sun, Evangeline Pierce, Hany Elmaraghy, Linda Stein-Gold
Publikováno v: Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractBackground Lebrikizumab improved itch, interference of itch on sleep, and quality of life (QoL) in patients with moderate-to-severe atopic dermatitis (AD), in two Phase 3 trials at 16 weeks compared to placebo.Objectives We assess improvement
Externí odkaz: https://doaj.org/article/c56bdf7a7a8a4644adf346f54f2ae8d3
Zobrazit plný text záznamu
2
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)
Autor: Esteban, Daudén, Pablo, de la Cueva, Laura, Salgado-Boquete, Mar, Llamas-Velasco, Eduardo, Fonseca, Ignasi, Pau-Charles, David, Asensio, Meritxell, Guilà, José Manuel, Carrascosa, Juan Ignacio, Yanguas
Publikováno v: Dermatology and therapy. 13(1)
Although dimethyl fumarate (DMF) has been approved since 2017 for treatment of moderate-to-severe plaque psoriasis, limited data on its safety and efficacy are available in clinical practice. The objective was to assess the efficacy and safety of DMF
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bb5b14578a154896dfa1d77723160cae
https://pubmed.ncbi.nlm.nih.gov/36456890
Zobrazit plný text záznamu
3
Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29(th) EADV virtual congress, 29-31 October 2020
Autor: Ina Hadshiew, Ignasi Pau-Charles, Pablo de la Cueva, Matthias Augustin, Ulrich Mrowietz, Meritxell Guilà, Andreu Schoenenberger, Mar Llamas-Velasco, Anna Ryzhkova, Sebastian Diemert, Astrid Kirsch, L. Salgado-Boquete, Christine Loew-Juettner, Francisco Javier Fernández-Soriano, Peter C.M. van de Kerkhof, Esteban Daudén, José Manuel Carrascosa
Publikováno v: Expert Review of Clinical Immunology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Expert Review of Clinical Immunology, 17, sup2, pp. 1-11
Expert Review of Clinical Immunology, 17, 1-11
Contains fulltext : 235283.pdf (Publisher’s version ) (Open Access) Background: The 29th EADV Virtual Congress took place between the 29th-31st of October 2020. On October 29th, there was a Session on systemic treatment in which Professors Ulrich M
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4326a6fd99955bc9d219f26c4964504c
https://doi.org/10.1080/1744666X.2021.1919510
Zobrazit plný text záznamu
4
Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate‐to‐severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials
Autor: Alexander Egeberg, Ignasi Pau-Charles, Paolo Gisondi, Denis Jullien, José Manuel Carrascosa, Diamant Thaçi, Jashin J. Wu
Publikováno v: Journal of the European Academy of Dermatology and Venereology. 35
In the context of the current coronavirus disease 2019 (COVID-19) pandemic, there is no direct evidence to support any preferred biologic therapy for psoriasis However, known safety profile of different classes of biologic therapies as well as indivi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dae974482d7a68720c503232189a6b3e
https://doi.org/10.1111/jdv.17427
Zobrazit plný text záznamu
6
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)
Autor: M. Falqués, Stephen J. Rozzo, Diamant Thaçi, Peter Foley, Z Draelos, Atsuyuki Igarashi, Stefano Piaserico, Richard B. Warren, Aditya K. Gupta, Wendy Cantrell, M Young, Alan M. Mendelsohn, A Asahina, Ignasi Pau-Charles, Kristian Reich, Richard G. Langley
Publikováno v: The British journal of dermatologyReferences. 185(2)
BACKGROUND: The phase III reSURFACE 1 and reSURFACE 2 (NCT01722331/NCT01729754) trials of the anti-interleukin-23p19 monoclonal antibody tildrakizumab (TIL) for psoriasis treatment are complete. OBJECTIVES: We present 5-year pooled data from reSURFAC
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5dbaf103becb747b42f93d34912636b
https://pubmed.ncbi.nlm.nih.gov/34031870
Zobrazit plný text záznamu
9
Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study
Autor: Ignasi Pau-Charles, Ulrich Mrowietz, P.C.M. van de Kerkhof, Robert Loewe, Jacek C Szepietowski, M. Falques
Publikováno v: JEADV : Journal of the European Academy of Dermatology and Venereology, 34, 1, pp. 119-126
JEADV : Journal of the European Academy of Dermatology and Venereology, 34, 119-126
Journal of the European Academy of Dermatology and Venereology
Contains fulltext : 218232.pdf (Publisher’s version ) (Open Access) BACKGROUND: Psoriasis is a chronic inflammatory skin disease associated with quality of life (QoL) impairment. BRIDGE was a randomized, double-blind, phase III study comparing the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01f903106534c79ecc3cd3bab28d67de
https://hdl.handle.net/2066/218232
Zobrazit plný text záznamu
10
Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data
Autor: Khusru Asadullah, Ulrich Mrowietz, Ignasi Pau-Charles, Lilla Landeck, Adriana Amasuno
Publikováno v: Archives of Dermatological Research
Fumarates (fumaric acid esters, FAEs) are orally administered systemic agents used for the treatment of psoriasis and multiple sclerosis. In 1994, a proprietary combination of FAEs was licensed for psoriasis by the German Drug Administration for use
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf2f3101c26f76dbe3a39aaaf807b2d0
https://doi.org/10.1007/s00403-018-1825-9
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje